Daiichi Sankyo Co Ltd

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q4 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States

Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio

Gilead Sciences

SANTA MONICA, Calif. & TOKYO--(BUSINESS WIRE)--Kite, a Gilead Company, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that YESCARTA® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, will be available to patients with relapsed or refractory large B-cell lymphomas in Japan through the first treatment center now authorized by Daiichi Sankyo. Kite and Daiichi Sankyo will also build on the exclusive licensing deal for commercialization rig

Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan

MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo to Present New Breast Cancer Data Across DXd ADC Portfolio at 2021 SABCS

Daiichi Sankyo to Present New Breast Cancer Data Across DXd ADC Portfolio at 2021 SABCS

Daiichi Sankyo Company Limited (DSKYF) CEO Sunao Manabe on Q2 2022 Results - Earnings Call Transcript

AstraZeneca

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki). The trial included HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma patients previously treated with a trastuzumab-containing regimen.

AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer

MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress

Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress

Roche Holding AG

AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu. The trial reached its primary endpoint in a study including HER2-positive metastatic breast cancer patients who had previously been treated with one prior line of HER2-based therapy.

AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer

Daiichi Sankyo Company Limited (DSKYF) Q1 2022 Results - Earnings Call Transcript

Daiichi Sankyo Co Ltd (OTC: DSKYF) and AstraZeneca plc (NASDAQ: AZN) have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (trastuzumab deruxtecan) for gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial will evaluate the safety and efficacy of Enhertu compared to ramucirumab/paclitaxel combination therapy in patients with HER2 positive metastatic or unresectable gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen.

Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu

Daiichi Sankyo Co Ltd (OTC: DSNKY) said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason. However, the Nikkei newspaper reported that there were safety concerns.

Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program that is showing promise in hard-to-treat breast cancer. The ADC, datopotamab deruxtecan, posted a 43% response rate and five confirmed complete or partial responses among 21 patients with triple-negative breast cancer, according to cohort data from the TROPION-PanTumor01 Phase 1 study presented at the virtual ESMO Breast annual meeting 2021.

AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer

Daiichi Sankyo Company Limited (DSKYF) CEO Sunao Manabe on Q4 2020 Results - Earnings Call Transcript

ContextLogic Inc

LEXINGTON, Mass., April 27, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (LogicBio - Nasdaq: LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the signing of a research collaboration and exclusive option agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo).

LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo

TOKYO & BASKING RIDGE, N.J. & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo) today announced the first patient has been dosed in the first-in-human phase 1/2 study of DS-1594, a selective small-molecule menin inhibitor, in adults with relapsed/refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial is being conducted by The University of Texas MD Anderson Cancer Center under an existing strategic research collaboration. Inhi

Phase 1/2 Trial Initiated for Daiichi Sankyo's Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Sanofi

Though Daiichi Sankyo (OTCMKTS: DSNKY) and Sanofi SA (NASDAQ: SNY) came forward to help produce other pharmas' COVID-19 shots, the companies are calling it quits on their own, separate vaccine alliance in Japan.  Daiichi Sankyo has decided to suspend the Squarekids combination vaccine production and a development deal for the pentavalent combination shot VN-0105 after encountering a manufacturing snag.

Daiichi Axes Sanofi Vaccine Pact After Pertussis Jab Manufacturing Faces Snag

Daiichi Sankyo (OTCMKTS: DSNKY) has begun a Phase 1/2 trial of DS-5670, its mRNA vaccine against COVID-19. Investigators are enrolling 152 healthy adults, including elderly individuals, in the trial.

Daiichi Takes mRNA COVID-19 Vaccine Into Human Trials

News for Daiichi Sankyo Co Ltd Stock (DSNKY)